Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Replimune secures accelerated approval for oncolytic viral therapy Tudriqev

7 August 2026 · By · Wire by Fusion42

Published

7 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 7 August 2026 · Fusion42 review

The US FDA granted accelerated approval to Replimune's oncolytic viral therapy Tudriqev for adult patients with advanced melanoma resistant to PD-1 blocking antibody treatments, marking the first approval for this specific patient group and combination with nivolumab.

This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 6 Aug 2026 and 10 Aug 2026.

◆ ◆ The Wire takeaway

You now face a clear regulatory route for viral therapies targeting checkpoint inhibitor-resistant melanoma, making combination immunotherapies a more viable product strategy this year.

◆ Coverage

14 sources · first reported 6 Aug 2026 · latest 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechoncolytic-virusmelanomafda-approvalimmunotherapyclinical-trials